Want to see NGNE full AI Analyst Report?
NGNE Stock Chart & Stats
$40.84
-$0.67(-1.88%)
At close: 4:00 PM EDT
$40.84
-$0.67(-1.88%)
Day’s Range― - ―
52-Week Range$15.93 - $43.66
Previous Close$34.9
Volume161.73K
Average Volume (3M)200.81K
Market Cap
$772.44M
Enterprise Value$492.21
Total Cash (Recent Filing)$225.39M
Total Debt (Recent Filing)$8.35M
Price to Earnings (P/E)―
Beta3.12
Next Earnings
Nov 23, 2026EPS Estimate
-1.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.51
Shares Outstanding20,011,381
10 Day Avg. Volume237,499
30 Day Avg. Volume200,811
Financial Highlights & Ratios
PEG Ratio5.20
Price to Book (P/B)1.65
Price to Sales (P/S)0.00
P/FCF Ratio-5.57
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$84.20Price Target Upside106.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-5.51
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Extended Cash RunwayFunding through early 2029 gives Neurogene time to advance clinical programs without immediate refinancing pressure. This supports sustained R&D execution, though future capital needs remain dependent on development progress.
Promising NGN-401 Clinical DataDurable, multidomain functional improvements and the absence of treatment-related serious events strengthen the clinical rationale for NGN-401. If replicated, these results could support differentiation in Rett syndrome and future regulatory progress.
Registrational Trial ProgressCompletion of dosing moves NGN-401 toward its planned registrational readout and potential BLA submission. Exceeding enrollment and maintaining acceptable tolerability improve execution visibility, although efficacy remains unproven until the planned analysis.
Bears Say
Pre-Revenue Business ModelNeurogene has no established commercial revenue base to offset substantial development spending. The company therefore remains dependent on successful clinical and regulatory outcomes before it can build recurring product revenue.
Escalating Cash BurnPersistent and rising cash consumption increases the amount of capital required to reach commercialization. Unless spending is controlled or revenue begins, additional financings could remain necessary and may pressure shareholder ownership.
Shrinking Equity And Financing DependenceAlthough leverage is low, declining equity shows that operations are consuming invested capital rather than compounding it. Continued reliance on equity funding can create dilution and leaves long-term financial strength tied to program success.
Neurogene News
NGNE FAQ
What was Neurogene’s price range in the past 12 months?
Neurogene lowest stock price was $15.93 and its highest was $43.66 in the past 12 months.
What is Neurogene’s market cap?
Neurogene’s market cap is $772.44M.
When is Neurogene’s upcoming earnings report date?
Neurogene’s upcoming earnings report date is Nov 23, 2026 which is in 77 days.
How were Neurogene’s earnings last quarter?
Neurogene released its earnings results on Aug 11, 2026. The company reported -$1.53 earnings per share for the quarter, missing the consensus estimate of -$1.423 by -$0.107.
Is Neurogene overvalued?
According to Wall Street analysts Neurogene’s price is currently Undervalued.
Does Neurogene pay dividends?
Neurogene does not currently pay dividends.
What is Neurogene’s EPS estimate?
Neurogene’s EPS estimate is -1.33.
How many shares outstanding does Neurogene have?
Neurogene has 20,011,381 shares outstanding.
What happened to Neurogene’s price movement after its last earnings report?
Neurogene reported an EPS of -$1.53 in its last earnings report, missing expectations of -$1.423. Following the earnings report the stock price went down -2.052%.
Which hedge fund is a major shareholder of Neurogene?
Currently, no hedge funds are holding shares in NGNE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neurogene Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$84.20 (106.17% Upside)
$84.20 (106.17% Upside)
Blogger Sentiment
Bearish
NGNE Sentiment 100%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Increased
By 252.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 10.7%
Last 30 Days ▲ 20.1%
Last 30 Days ▲ 20.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
96.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-17.81%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Neurogene
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
NGNE Stock 12 Month Forecast
Average Price Target
$84.20
▲(106.17% Upside)
Technical Analysis
Silence Therapeutics
―
Atea Pharmaceuticals
―
Elicio Therapeutics
―
Vor Biopharma
―
Tenaya Therapeutics
―
Ownership Overview
7.35% Insiders
6.59% Mutual Funds
54.56% Other Institutional Investors
22.35% Public Companies and
Individual Investors